These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39181430)

  • 21. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
    Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L
    World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
    Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
    Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
    Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
    J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of chronic hepatitis B.
    Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
    Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
    Xu JH; Fan YN; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
    J Viral Hepat; 2022 Oct; 29(10):862-867. PubMed ID: 35737855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia.
    Zhou K; Wahed AS; Cooper S; Di Bisceglie AM; Fontana RJ; Ghany MG; Khalili M; Lok AS; Perrillo R; Lee WM; Lau DTY; Sterling R; Janssen HLA; Terrault NA
    Am J Gastroenterol; 2019 Nov; 114(11):1753-1763. PubMed ID: 31658127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Lin HC; Jeng WJ; Liu J; Pan MH; Lee MH; Batrla-Utermann R; Lu SN; Chen CF; Yang HI; Chen CJ
    Aliment Pharmacol Ther; 2024 Apr; 59(8):993-1002. PubMed ID: 38410882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
    Wu Y; Wen J; Tang G; Zhang J; Xin J
    J Infect; 2021 Nov; 83(5):594-600. PubMed ID: 34474058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers.
    Tseng TC; Liu CJ; Chen CL; Yang HC; Su TH; Wang CC; Yang WT; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2013 Aug; 208(4):584-93. PubMed ID: 23656977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
    Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
    J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study].
    Zhou Y; Hu C; Yuan G; Liu J; Ren Y; Tang C; Yang S; Dai L; Li Y; Yang D
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):633-640. PubMed ID: 31270040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma.
    Kim SR; Kim SK
    Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
    Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
    J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.